Results 191 to 200 of about 10,401 (200)

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab

American Journal of Respiratory and Critical Care Medicine, 2018
Manali Mukherjee, Melanie Kjarsgaard, Nicola LaVigne   +2 more
exaly  

Real-World Effectiveness and the Characteristics of a “Super-Responder” to Mepolizumab in Severe Eosinophilic Asthma

Chest, 2020
Grainne D'ancona, Jaideep Dhariwal, Brian D Kent   +2 more
exaly  

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

New England Journal of Medicine, 2009
Pranabashis Haldar, Christopher E Brightling, Sumit Gupta   +2 more
exaly  

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

New England Journal of Medicine, 2017
Michael E Wechsler, Praveen Akuthota, David Jayne   +2 more
exaly  

The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma

Allergy: European Journal of Allergy and Clinical Immunology, 2019
Kenneth R Chapman, Frank C Albers, Xavier Muñoz Gall   +2 more
exaly  

Mepolizumab

Drugs of the Future, 2007
null Revill, P., null Mealy, N.
openaire   +1 more source

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

New England Journal of Medicine, 2009
Parameswaran Nair, Melanie Kjarsgaard, Emilio Pizzichini   +2 more
exaly  

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study

Clinical Therapeutics, 2016
Richard Leigh, Robert G Price, Steven W Yancey   +2 more
exaly  

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease

New England Journal of Medicine, 2017
Ian D Pavord, Gerard J Criner, Huib A M Kerstjens   +2 more
exaly  

Mepolizumab

Reactions Weekly, 2017
openaire   +2 more sources